Who can use Bavencio(Avelumab)?

This medicine is approved for metastatic Merkel cell carcinoma, specific stages of urothelial carcinoma, and advanced renal cell carcinoma.

Approved Oncological Uses

BAVENCIO is indicated for three primary oncological settings. For Merkel cell carcinoma (MCC), it is used in adults and pediatric patients aged 12 years and older with metastatic disease. In urothelial carcinoma (UC), its uses include maintenance treatment for locally advanced or metastatic disease that has not progressed on first-line platinum chemotherapy, and for treating disease that has progressed during or after platinum-based therapy. For renal cell carcinoma (RCC), it is indicated in combination with axitinib for the first-line treatment of patients with advanced disease.